Literature DB >> 11882786

Updated assessment of cystic fibrosis mutation frequencies in non-Hispanic Caucasians.

Glenn E Palomaki1, James E Haddow, Linda A Bradley, Stacey C FitzSimmons.   

Abstract

PURPOSE: To update estimates of individual and cumulative cystic fibrosis (CF) mutation frequencies in non-Hispanic Caucasians for the prenatal screening panel recommended by American College of Medical Genetics and to determine the impact on screening performance.
METHODS: Two data sources were used. In the first (CF Genetic Analysis Consortium), our re-analysis was restricted to North American studies. In the second (CF Foundation National Patient Registry), we performed a new analysis restricted to individuals tested at eight Therapeutic Development Network sites.
RESULTS: The updated average cumulative proportion of mutations identified is 88.34% (higher than previously reported), indicating that 78% of high-risk couples (and affected fetuses) can potentially be identified.
CONCLUSION: Prenatal CF screening in U.S. non-Hispanic Caucasians is more effective than previously thought.

Entities:  

Mesh:

Year:  2002        PMID: 11882786     DOI: 10.1097/00125817-200203000-00007

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  10 in total

1.  Detection of an apparent homozygous 3120G>A cystic fibrosis mutation on a routine carrier screen.

Authors:  Denise LaMarche Heaney; Patrick Flume; Lauren Hamilton; Elaine Lyon; Daynna J Wolff
Journal:  J Mol Diagn       Date:  2006-02       Impact factor: 5.568

2.  A comparative study of five technologically diverse CFTR testing platforms.

Authors:  Monique A Johnson; Marvin J Yoshitomi; C Sue Richards
Journal:  J Mol Diagn       Date:  2007-07       Impact factor: 5.568

3.  Technical validation of a TM Biosciences Luminex-based multiplex assay for detecting the American College of Medical Genetics recommended cystic fibrosis mutation panel.

Authors:  Charles M Strom; Richard Janeszco; Franklin Quan; Sheng-biao Wang; Arlene Buller; Matthew McGinniss; Weimin Sun
Journal:  J Mol Diagn       Date:  2006-07       Impact factor: 5.568

4.  Changing incidence of cystic fibrosis in Wisconsin, USA.

Authors:  Katelyn Parker-McGill; Melodee Nugent; Rachel Bersie; Gary Hoffman; Michael Rock; Mei Baker; Philip M Farrell; Pippa Simpson; Hara Levy
Journal:  Pediatr Pulmonol       Date:  2015-08-10

5.  Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report.

Authors:  Philip M Farrell; Beryl J Rosenstein; Terry B White; Frank J Accurso; Carlo Castellani; Garry R Cutting; Peter R Durie; Vicky A Legrys; John Massie; Richard B Parad; Michael J Rock; Preston W Campbell
Journal:  J Pediatr       Date:  2008-08       Impact factor: 4.406

6.  The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group.

Authors:  Steven M Teutsch; Linda A Bradley; Glenn E Palomaki; James E Haddow; Margaret Piper; Ned Calonge; W David Dotson; Michael P Douglas; Alfred O Berg
Journal:  Genet Med       Date:  2009-01       Impact factor: 8.822

7.  Chapter 11: challenges in and principles for conducting systematic reviews of genetic tests used as predictive indicators.

Authors:  Daniel E Jonas; Timothy J Wilt; Brent C Taylor; Tania M Wilkins; David B Matchar
Journal:  J Gen Intern Med       Date:  2012-06       Impact factor: 5.128

8.  CFTR Modulator Use Is Associated with Higher Hemoglobin Levels in Individuals with Cystic Fibrosis.

Authors:  Alex H Gifford; Sonya L Heltshe; Christopher H Goss
Journal:  Ann Am Thorac Soc       Date:  2019-03

Review 9.  Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders.

Authors:  Samuel M Moskowitz; James F Chmiel; Darci L Sternen; Edith Cheng; Ronald L Gibson; Susan G Marshall; Garry R Cutting
Journal:  Genet Med       Date:  2008-12       Impact factor: 8.822

Review 10.  Genetic Testing in the Diagnosis of Primary Ciliary Dyskinesia: State-of-the-Art and Future Perspectives.

Authors:  Samuel A Collins; Woolf T Walker; Jane S Lucas
Journal:  J Clin Med       Date:  2014-05-09       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.